Eli Lilly CEO still believes in that $5B budget for R&D

Eli Lilly ($LLY) CEO John Lechleiter says he's standing by his plans to invest big money into R&D, rather than cutting expenses to prepare for new generic competition. Lechleiter tells The Wall Street Journal that he sees "the light at the end of the tunnel," but if pipeline failures continue, then cuts would have to follow. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.